{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:50:44Z","timestamp":1790049044125,"version":"4.0.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.drudis.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:34:36Z","timestamp":1564745676000},"page":"2033-2043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["The influence of ketamine on drug discovery in depression"],"prefix":"10.1016","volume":"24","author":[{"given":"Christoph","family":"Kraus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Acevedo-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashkim","family":"Kadriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.07.007_bib0005","series-title":"Director\u2019s Blog: Ketamine","author":"Insel","year":"2014"},{"key":"10.1016\/j.drudis.2019.07.007_bib0010","series-title":"Depression Fact Sheet","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.drudis.2019.07.007_bib0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drudis.2019.07.007_bib0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/bja\/77.4.441","article-title":"Ketamine: its mechanism(s) of action and unusual clinical uses","volume":"77","author":"Hirota","year":"1996","journal-title":"Br. J. Anaesth"},{"key":"10.1016\/j.drudis.2019.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ajem.2017.02.026","article-title":"Ketamine as a first-line treatment for severely agitated emergency department patients","volume":"35","author":"Riddell","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drudis.2019.07.007_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1207\/s15473333thp3404_7","article-title":"Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism","volume":"34","author":"Kolp","year":"2006","journal-title":"The Humanistic Psychologist"},{"key":"10.1016\/j.drudis.2019.07.007_bib0045","first-page":"20","article-title":"Terapia antidepressiva con Ci 581 (ketamine)","volume":"4","author":"Fontana","year":"1974","journal-title":"Acta Psiquiat. Psicol. Am. Lat."},{"key":"10.1016\/j.drudis.2019.07.007_bib0050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"suppl. 6","key":"10.1016\/j.drudis.2019.07.007_bib0060","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: from monoamines to glutamate","volume":"23","author":"Hillhouse","year":"2015","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/science.2704997","article-title":"Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus","volume":"244","author":"Shors","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.07.007_bib0080","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005710","article-title":"NMDA receptor-dependent long-term potentiation and long-term depression (LTP\/LTD)","volume":"4","author":"Luscher","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(95)00155-P","article-title":"Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)","volume":"52","author":"Layer","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drudis.2019.07.007_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","article-title":"Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression","volume":"263","author":"Papp","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0105","series-title":"Ketamine for Treatment-Resistant Depression: The First Decade of Progress","first-page":"31","article-title":"Ketamine: clinical studies in treatment-resistant depressive disorders","author":"Blier","year":"2016"},{"key":"10.1016\/j.drudis.2019.07.007_bib0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13651501.2016.1254802","article-title":"Administration of ketamine for unipolar and bipolar depression","volume":"21","author":"Kraus","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.drudis.2019.07.007_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1192\/bjp.bp.113.143701","article-title":"Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up","volume":"207","author":"Tajika","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here","volume":"72","author":"aan het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0145","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.npp.1300341","article-title":"Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression","volume":"29","author":"Katz","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0150","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.13m08744","article-title":"Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders","volume":"75","author":"Leon","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0155","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","article-title":"Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety","volume":"58","author":"Ballard","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.drudis.2019.07.007_bib0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2016.01.009","article-title":"An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder","volume":"194","author":"Saligan","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drudis.2019.07.007_bib0170","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0269881114568041","article-title":"Neural correlates of change in major depressive disorder anhedonia following open-label ketamine","volume":"29","author":"Lally","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2017.03.011","article-title":"Motor-activity markers of circadian timekeeping are related to ketamine\u2019s rapid antidepressant properties","volume":"82","author":"Duncan","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0190","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0195","series-title":"FDA approves new nasal spray medication for treatment-resistant depression","author":"US Food & Drug Administration","year":"2019"},{"key":"10.1016\/j.drudis.2019.07.007_bib0200","series-title":"FDA Briefing Document","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.drudis.2019.07.007_bib0205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2019.07.007_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments","volume":"22","author":"Kadriu","year":"2019","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.drudis.2019.07.007_bib0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.07.007_bib0220","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0225","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0230","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14656566.2019.1583743","article-title":"State of the art opioid-sparing strategies for post-operative pain in adult surgical patients","volume":"20","author":"Gabriel","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2019.07.007_bib0235","first-page":"1186","article-title":"Ketamine: teaching an old drug new tricks","volume":"87","author":"Kohrs","year":"1998","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.drudis.2019.07.007_bib0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ijnp\/pyx085","article-title":"Assessment of ketamine binding of the serotonin transporter in humans with positron emission tomography","volume":"21","author":"Spies","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0245","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.07.007_bib0250","article-title":"Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind, placebo-controlled, cross-over, randomized clinical trial","author":"Abdallah","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2019.07.007_bib0255","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03581","article-title":"GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine","volume":"3","author":"Miller","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2019.07.007_bib0260","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature25509","article-title":"Ketamine blocks bursting in the lateral habenula to rapidly relieve depression","volume":"554","author":"Yang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.07.007_bib0265","doi-asserted-by":"crossref","first-page":"15755","DOI":"10.1073\/pnas.1513913112","article-title":"Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats","volume":"112","author":"Choi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.07.007_bib0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.biopsych.2016.06.012","article-title":"Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles","volume":"81","author":"Bagot","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0275","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8078","article-title":"Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation","volume":"364","author":"Moda-Sava","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.07.007_bib0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1126\/science.aax0719","article-title":"Do antidepressants restore lost synapses?","volume":"364","author":"Beyeler","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.07.007_bib0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpba.2016.03.030","article-title":"Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats","volume":"127","author":"Moaddel","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2019.07.007_bib0290","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.talanta.2010.08.005","article-title":"A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome","volume":"82","author":"Moaddel","year":"2010","journal-title":"Talanta"},{"key":"10.1016\/j.drudis.2019.07.007_bib0295","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.07.007_bib0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2019.07.007_bib0305","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.07.007_bib0310","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.07.007_bib0315","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14737175.2017.1283217","article-title":"Investigational drugs in recent clinical trials for treatment-resistant depression","volume":"17","author":"Garay","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.drudis.2019.07.007_bib0320","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","article-title":"Glutamatergic modulators in depression","volume":"26","author":"Henter","year":"2018","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0325","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0330","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S1461145705005900","article-title":"Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine","volume":"9","author":"Amargos-Bosch","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0335","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.mp.4001093","article-title":"NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia","volume":"7","author":"Kapur","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.biopsych.2015.04.007","article-title":"Potential pathways involved in the rapid antidepressant effects of nitrous oxide","volume":"78","author":"Zarate","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0345","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0350","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","article-title":"Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression","volume":"74","author":"Huang","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0355","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neuropharm.2009.07.019","article-title":"The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist","volume":"57","author":"Zhang","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0360","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.07.007_bib0365","series-title":"FDA approves first treatment for post-partum depression","author":"FDA","year":"2019"},{"key":"10.1016\/j.drudis.2019.07.007_bib0370","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.07.007_bib0375","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2019.07.007_bib0380","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.07.007_bib0385","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, Phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.07.007_bib0390","article-title":"A pivotal study of the oral GABA-A receptor positive allosteric modulator SAGE-217 in major depressive disorder: analysis of HAM-D total score, subscales and individual items","author":"Gunduz-Bruce","year":"2019","journal-title":"Presented at: American Society of Clinical Psychopharmacology Annual Meeting"},{"key":"10.1016\/j.drudis.2019.07.007_bib0395","series-title":"Sage announces pivotal Phase 3 trial status for SAGE-217 in major depressive disorder and postpartum depression based on FDA breakthrough therapy meeting","author":"Sage Therapeutics","year":"2018"},{"key":"10.1016\/j.drudis.2019.07.007_bib0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.drudis.2019.07.007_bib0405","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr. Neuropharmacol"},{"key":"10.1016\/j.drudis.2019.07.007_bib0410","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0415","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","article-title":"Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial","volume":"173","author":"Yovell","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0420","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0425","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0430","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0435","series-title":"FDA rejects Alkermes\u2019 depression drug ALKS 5461","author":"FierceBiotech","year":"2019"},{"key":"10.1016\/j.drudis.2019.07.007_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0445","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.108.12.896","article-title":"Lysergic acid diethylamide (LSD-25): a clinical-psychological study","volume":"108","author":"Savage","year":"1952","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0450","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.186.6.457","article-title":"Can psychedelics have a role in psychiatry once again?","volume":"186","author":"Sessa","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0455","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","article-title":"Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research","volume":"32","author":"Hermle","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0460","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0465","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0470","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"Osorio Fde","year":"2015","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0475","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0485","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0490","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0495","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0500","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0505","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.007_bib0510","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/mp.2013.144","article-title":"Serotonin 2C receptor antagonists induce fast-onset antidepressant effects","volume":"19","author":"Opal","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0515","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.drudis.2019.07.007_bib0520","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neubiorev.2017.03.007","article-title":"Serotonin and neuroplasticity \u2013 links between molecular, functional and structural pathophysiology in depression","volume":"77","author":"Kraus","year":"2017","journal-title":"Neurosci. Biobehav. Rev"},{"key":"10.1016\/j.drudis.2019.07.007_bib0525","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.007_bib0530","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.007_bib0535","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12728","article-title":"A report of affective switching associated with ketamine: the case of ketamine-induced mania is not closed","volume":"21","author":"Allen","year":"2019","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.drudis.2019.07.007_bib0540","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biopsych.2013.01.038","article-title":"Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression","volume":"74","author":"Niciu","year":"2013","journal-title":"Biol. Psychiatry"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619302831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619302831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:40:17Z","timestamp":1761223217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644619302831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1359644619302831"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.07.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of ketamine on drug discovery in depression","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}